Inhaled anticholinergics may be the first-line therapy for stable COPD. However, the effect of inhaled anticholinergic agents on exercise capacity is still controversial. Fourteen patients with stable COPD (age, 64.6 ± 5.9 years) completed a randomized, double-blind placebo-controlled crossover trial. All the patients were studied by symptom-limited progressive cycle ergometry before and 90 min after the inhalation of either oxitropium bromide, 800 ,ug, or an identical placebo. 
Inhaled anticholinergics may be the first-line therapy for stable COPD. However, the effect of inhaled anticholinergic agents on exercise capacity is still controversial. Fourteen patients with stable COPD (age, 64.6 ± 5.9 years) completed a randomized, double-blind placebo-controlled crossover trial. All the patients were studied by symptom-limited progressive cycle ergometry before and 90 min after the inhalation of either oxitropium bromide, 800 ,ug, or an identical placebo.
Spirometry was assessed before and after each exercise test. While FEV, averaged 0.85 ± 0.34 L at 90 min after the inhalation of placebo, FEV1 was 1.01 ± 0.41 L at 90 min after the inhalation of oxitropium, 800 ,ug (significant from placebo, p<0.001). The maximal workload of 94.0 ± 25.8 W after oxitropium administration was significantly greater than the 87.6 ± 24.7 W measured after placebo (p<0.01). The maximal minute ventilation was 40.2 ± 12.3 L/min after oxitropium inhalation and 36.8 ± 10.5 after placebo inhalation (p<0.05). The differences in maximal oxygen consumption, maximal carbon dioxide production, and maximal heart rate between oxitropium and placebo inhalation also were patients with COPD complain of dyspnea and exertional intolerance. In these patients, functional exercise capacity is generally thought to be curtailed by limited breathing capacity and impaired gas exchange. Therapy with bronchodilators frequently is used in an attempt to relieve symptoms Upon admission into the study the subjects underwent an evaluation including complete blood cell count, automated blood chemical analysis, serum immunoglobulin E assay, sputum examination, and an ECG. All patients underwent baseline pulmonary function testing after the withdrawal of bronchodilators. In accordance with the method described in the American Thoracic Society 1987 update,16 spirometric testing for determining the FEV1, FVC, and FEVI/FVC ratio was performed using a spirometer (AUTOSPIRO AS-600, Minato Medical Science Co. Ltd, Osaka, Japan) which was calibrated with a 3.0-L syringe before every measurement. The largest FEV, and the largest FVC among three maneuvers were analyzed. The predicted values of FEV, and FVC were those of the Japan Society of Chest Diseases.17 Functional residual capacity (FRC) was determined by plethysmography (MBR-600, Nihon Kohden Co, Tokyo, Japan), and residual volume was calculated as FRC minus expiratory reserve volume measured by spirometric testing. Total lung capacity (TLC) was determined as the sum of vital capacity (VC) and residual volume. Static compliance and airway resistance were also measured by plethysmography. The single-breath diffusing capacity for carbon monoxide (Dsb) was measured (Chestac-65, Chest, Tokyo).
Progressive Exercise Test
The progressive exercise test to a symptom-limited maximum was performed on a calibrated electrically braked cycle ergometer (Corival WLP-400, Lode, Groningen, the Netherlands). Subjects breathed through a high-velocity, low-resistance unidirectional valve (Rudolph face mask exercise testing, Hans Rudolph, Inc, Kansas City, MO) with simultaneous breath-by-breath measurement using an exercise testing system (Desktop Diagnostics/CPX, Medical Graphic Corporation, St. Paul, Minn). Minute ventilation (VE) and oxygen and carbon dioxide tension in the expired air were determined every eight breaths by a rapidly responding analyzer and the mean VE, oxygen consumption (Vo2), and carbon dioxide production (Vco2) were then calculated. The analyzer was calibrated just before the study with known gas mixtures: (1) the oxygen analyzer with air (20.93% oxygen) and a 15% oxygen mixture and (2) the carbon dioxide analyzer with air and a 5% carbon dioxide mixture. Patients began unloaded cycling for 3 min, after which the power output was increased progressively at the rate of 20 W/min until the patient could no longer continue the required cadence of 40 revolutions per minute due to severe dyspnea or exhaustion. Arterial oxygen saturation (SaO2) was measured continuously by pulse oximetry (N-200 pulse oximeter, Nellcor Inc, Hayward, Calif) and heart rate (HR) by electrocardiography (Life Scope 8, Nihon Koden Co, Tokyo, Japan). At the end of each exercise, symptoms of leg effort and breathlessness were scored with the Borg scale (0 to 10), which was presented within easy view of the subject. None by the Spearman rank correlation test. A probability value of less than 0.05 was considered to be statistically significant for all tests.
RESULTS
Fourteen male patients completed the entire study. The clinical background and the results of baseline tests of pulmonary function in these patients are summarized in Table 1 . Their mean age was 67.6 ± 6.4 years (range, 56 to 78 years). All had spirometric evidence of severe airflow obstruction with a mean FEV1 of 0.85±0.34 L (33.3±13.1% of predicted). The patients were mildly hypoxemic when breathing room air, with a mean PaO2 of 77.0±8.6 mm Hg. The TLC averaged 155% of predicted because FRC was determined using body plethysmography.
The resting pulse rates measured before spirometry were similar before inhalation but increased significantly more after inhalation of oxitropium than after placebo inhalation ( Table 2 ). Blood pressure was not different after administration of oxitropium or placebo in four measurements for the individual. No patient complained of adverse symptoms.
The results of the spirometric measurements in the study are shown in Figure 1 and Table 2 . The FEV1 and FVC were identical prior to inhalation for both placebo and oxitropium. After all four progressive cycle ergometries (two on each test day), there were no significant changes in spirometric variables compared with values before exercise. Inhalation of oxitropium, 800 Ag, resulted in significant changes in airflow limitation. At 90 min after inhalation of oxitropium, 800 ,ug (before exercise values, second exercise), FEV1 and FVC were significanty improved from levels after administration of placebo (p<0.001 and p<0.01, respectively). This significant improvement, owing to inhalation of oxitropium, was similarly shown at 120 min after inhalation (after exercise values, second exercise).
The results of progressive cycle ergometry before inhalation were similar on the two separate test days (Table 3) . Furthermore, the maximal work rate, maximal VE, VO2, VCO2, HR, oxygen pulse, and Borg scale at maximal exercise after inhalation of the placebo were also similar to values recorded prior to the inhalation.
Maximal exercise capacity was 86. Vco2, and maximal HR between oxitropium inhalation and placebo inhalation also were statistically significant (p<0.05, p<0.O5, and p<0.01, respectively). The SaO2, and oxygen pulse at maximum exercise and dyspnea as measured on the Borg scale at the end of the test were not different between the two groups.
To determine whether the observed improvement in exercise capacity was related to individual improvements in airflow limitation, we examined the relationship between FEV1 and maximal workload for all 28 tests, ie, 1 test with oxitropium and 1 with placebo for each patient. A significant correlation was found between the change in maximal workload and the change in FEV1 (r=0.625, p<0.01 [Fig 2] ).
DISCUSSION
The present study is the first comprehensive report to establish that an inhaled anticholinergic agent can improve exercise capacity in patients with COPD.
While FEV1 and FVC increased significantly after the inhalation of oxitropium bromide, 800 Mug, compared with placebo inhalation, many parameters obtained during symptom-limited progressive cycle ergometry (maximum values of the following: workload, VE, Vo2, VCO2, and HR) also were improved.
There was a good correlation between the change in maximal workload and the change in FEy1, suggest- Dullinger et al19 reported that inhaled metaproterenol has no effect on the 12- Orally administrated theophylline has been employed for several decades2 as a bronchodilator. In addition, theophylline may improve exercise tolerance, prevent the development of the sensation of dyspnea during exercise, and reduce the incidence of dyspnea. These effects of theophylline are most likely related to improvements in respiratory muscle performance rather than bronchodilation.29 '30 It was reported that both theophylline and inhaled metaproterenol can ameliorate exercise intolerance without remarkable bronchodilation.'1920 Some investigators pointed out that it is necessary to reevaluate the role of oral administration of theophylline combined with inhaled bronchodilators for stable COPD.2 Thus, the effect of combined bronchodilator therapy on exercise capacity should be evaluated further.
In conclusion, the inhalation of oxitropium bromide, 800,g, can improve the exercise capacity in patients with stable COPD. This effect most likely depends on significant bronchodilation, and inhaled anticholinergic agents can be the first-line therapy for stable COPD.
